LU92853I2 - Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine et l'emtricitabine - Google Patents
Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine et l'emtricitabine Download PDFInfo
- Publication number
- LU92853I2 LU92853I2 LU92853C LU92853C LU92853I2 LU 92853 I2 LU92853 I2 LU 92853I2 LU 92853 C LU92853 C LU 92853C LU 92853 C LU92853 C LU 92853C LU 92853 I2 LU92853 I2 LU 92853I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- rilpivirine
- emtricitabine
- protected
- pharmaceutically acceptable
- combination
- Prior art date
Links
- 229960002814 rilpivirine Drugs 0.000 title 2
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 title 2
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 title 1
- 229960000366 emtricitabine Drugs 0.000 title 1
- KZVVGZKAVZUACK-BJILWQEISA-N rilpivirine hydrochloride Chemical class Cl.CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 KZVVGZKAVZUACK-BJILWQEISA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49977103P | 2003-09-03 | 2003-09-03 | |
EP03103275 | 2003-09-03 | ||
EP03103319 | 2003-09-08 | ||
EP03103335 | 2003-09-10 | ||
EP03103668 | 2003-10-02 | ||
US50848603P | 2003-10-03 | 2003-10-03 | |
EP04787096.9A EP1663240B2 (en) | 2003-09-03 | 2004-09-03 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
PCT/EP2004/052028 WO2005021001A1 (en) | 2003-09-03 | 2004-09-03 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
LU92853I2 true LU92853I2 (fr) | 2015-12-21 |
Family
ID=34280181
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU92853C LU92853I2 (fr) | 2003-09-03 | 2015-10-20 | Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine et l'emtricitabine |
LU92855C LU92855I2 (fr) | 2003-09-03 | 2015-10-21 | Combinaison de rilpivirine ou une forme thérapeutique equivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, ténofovir, en particulier le fumarate de ténofovir disoproxil, et l'emtricitabine |
LU92854C LU92854I2 (fr) | 2003-09-03 | 2015-10-21 | Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU92855C LU92855I2 (fr) | 2003-09-03 | 2015-10-21 | Combinaison de rilpivirine ou une forme thérapeutique equivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, ténofovir, en particulier le fumarate de ténofovir disoproxil, et l'emtricitabine |
LU92854C LU92854I2 (fr) | 2003-09-03 | 2015-10-21 | Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil |
Country Status (25)
Country | Link |
---|---|
US (9) | US20080200435A1 (ja) |
EP (1) | EP1663240B2 (ja) |
JP (3) | JP5507791B2 (ja) |
KR (1) | KR20060090658A (ja) |
CN (1) | CN101060844B (ja) |
AP (1) | AP2109A (ja) |
AU (5) | AU2004268390B2 (ja) |
BE (1) | BE2015C053I2 (ja) |
CA (1) | CA2537095C (ja) |
CY (5) | CY2015039I1 (ja) |
FI (1) | FI1663240T4 (ja) |
FR (3) | FR15C0073I2 (ja) |
HK (1) | HK1092698A1 (ja) |
HR (1) | HRP20150798T4 (ja) |
HU (5) | HUS1500054I1 (ja) |
IL (2) | IL173438A (ja) |
LT (2) | LTPA2016045I1 (ja) |
LU (3) | LU92853I2 (ja) |
MX (1) | MXPA06002437A (ja) |
MY (1) | MY169670A (ja) |
NL (2) | NL300781I1 (ja) |
NO (5) | NO334877B1 (ja) |
NZ (1) | NZ545306A (ja) |
PL (1) | PL1663240T5 (ja) |
WO (1) | WO2005021001A1 (ja) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8101629B2 (en) | 2001-08-13 | 2012-01-24 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
US7638522B2 (en) | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
CN100554245C (zh) | 2002-08-09 | 2009-10-28 | 詹森药业有限公司 | 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法 |
EP3025718A1 (en) | 2003-01-14 | 2016-06-01 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
EP1632232B3 (en) * | 2004-09-02 | 2022-03-30 | Janssen Pharmaceutica NV | Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile |
ATE550074T1 (de) * | 2004-09-02 | 2012-04-15 | Janssen Pharmaceutica Nv | Fumarat aus 4-((4-((4-(2-cyanoethenyl)-2,6- dimethylphenyl amino -2-pyrimidinyl amino benzonitril |
UA92469C2 (en) * | 2004-09-02 | 2010-11-10 | Янссен Фармацевтика Н.В. | Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile |
AU2005279158C1 (en) * | 2004-09-02 | 2010-12-16 | Janssen Pharmaceutica N.V. | Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile |
EP1789139B1 (en) * | 2004-09-02 | 2012-03-21 | Janssen Pharmaceutica NV | Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl amino -2-pyrimidinyl amino benzonitrile |
TW201414495A (zh) * | 2005-04-04 | 2014-04-16 | Tibotec Pharm Ltd | Hiv-感染之預防 |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
RU2008128424A (ru) * | 2005-12-14 | 2010-01-20 | Сипла Лимитед (In) | Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы |
RS52821B2 (sr) * | 2006-01-20 | 2021-07-30 | Janssen Sciences Ireland Unlimited Co | Dugotrajno tretiranje hiv-infekcije sa tcm278 |
US9044509B2 (en) | 2006-02-03 | 2015-06-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibition of HIV infection through chemoprophylaxis |
FR2903312B1 (fr) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament |
AR065720A1 (es) * | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. |
AU2008353145B2 (en) * | 2008-01-03 | 2013-09-12 | Universite D' Aix-Marseille | Bitherapy and tritherapy used for treating an HIV-positive patient |
SG196774A1 (en) * | 2008-12-24 | 2014-02-13 | Tibotec Pharm Ltd | Implantable devices for treating hiv |
KR101798430B1 (ko) | 2009-12-21 | 2017-11-16 | 얀센 사이언시즈 아일랜드 유씨 | 활성 화합물의 서방출을 위한 분해 및 제거가능한 임플란트 |
AP3551A (en) | 2010-01-27 | 2016-01-18 | Viiv Healthcare Co | Antiviral therapy |
BR112013012245B1 (pt) | 2010-11-19 | 2022-09-27 | Janssen Sciences Ireland Uc | Comprimido compreendendo hcl de rilpivirina e fumarato de tenofovir disoproxila seu uso no tratamento profilático ou terapêutico de uma infecção por hiv |
WO2012125993A1 (en) | 2011-03-17 | 2012-09-20 | Teva Pharmaceutical Industries Ltd. | Solid state forms of rilpivirine base, and rilipivirine salts |
ES2680146T3 (es) * | 2011-09-16 | 2018-09-04 | Hetero Research Foundation | Hidrocloruro de rilpivirina |
CA3012242C (en) | 2012-12-21 | 2021-11-02 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
EP3632415A1 (en) | 2015-11-09 | 2020-04-08 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
EP3528791B1 (en) | 2016-10-24 | 2023-12-06 | Janssen Sciences Ireland Unlimited Company | Dispersible compositions |
WO2018119371A1 (en) * | 2016-12-23 | 2018-06-28 | Temple University - Of The Commonwealth System Of Higher Education | Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis) |
AU2018255954B2 (en) * | 2017-04-18 | 2024-04-04 | Cipla Limited | Combination therapy for use in treating retroviral infections |
WO2019021319A1 (en) * | 2017-07-27 | 2019-01-31 | Cipla Limited | PHARMACEUTICAL COMPOSITIONS |
WO2021104487A1 (en) | 2019-11-29 | 2021-06-03 | Aptorum Therapeutics Limited | Composition including rilpivirine and use thereof for treating tumors or cancer |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5182111A (en) | 1987-11-17 | 1993-01-26 | Boston University Research Foundation | In vivo delivery of active factors by co-cultured cell implants |
US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
GB8815265D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
US5368864A (en) | 1988-11-25 | 1994-11-29 | Henning Berlin Gmbh Chemie- Und Pharmawerk | Formulation of oxypurinol and/or its alkali and alkaline earth salts |
MY104575A (en) | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
EP0489181B1 (en) | 1990-07-19 | 1996-10-02 | Otsuka Pharmaceutical Co., Ltd. | Solid preparation |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
WO1993009176A2 (en) | 1991-10-29 | 1993-05-13 | Clover Consolidated, Limited | Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release |
ATE184787T1 (de) | 1992-05-13 | 1999-10-15 | Wellcome Found | Therapeutische kombinationen |
JPH06316524A (ja) | 1992-09-11 | 1994-11-15 | Naoyuki Inoue | 抗エイズウイルス剤 |
TW401303B (en) | 1994-07-01 | 2000-08-11 | Janssen Pharmaceutica Nv | Anti-HIV triple combination |
IT1281502B1 (it) * | 1995-06-13 | 1998-02-18 | Sardinian Antiviral Research C | Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della |
US6045829A (en) | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
WO2001021154A2 (en) | 1999-09-21 | 2001-03-29 | Rtp Pharma Inc. | Surface modified particulate compositions of biologically active substances |
US6743446B2 (en) | 1999-12-15 | 2004-06-01 | The Ohio State University Research Foundation | Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers |
TW200800298A (en) | 2000-01-27 | 2008-01-01 | Zentaris Ag | Compressed microparticles for dry injection |
IL151475A0 (en) | 2000-03-30 | 2003-04-10 | Bristol Myers Squibb Co | Beadlets containing stavudine |
US20040115268A1 (en) | 2000-04-26 | 2004-06-17 | Control Delivery Systems, Inc. | Systemic delivery of antiviral agents |
DE10050199A1 (de) | 2000-10-11 | 2002-04-25 | Ethicon Gmbh | Flächiges Implantat mit im Ultraschall detektierbaren Elementen |
EP1350792A1 (en) | 2000-12-11 | 2003-10-08 | Takeda Chemical Industries, Ltd. | Medicinal compositions improved in solublity in water |
ATE444060T1 (de) | 2001-06-22 | 2009-10-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren |
JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
EP1458361A4 (en) | 2001-11-20 | 2007-04-25 | Advanced Inhalation Res Inc | COMPOSITIONS FOR DISTRIBUTING PRODUCTS WITH LASTING EFFECT |
CN100554245C (zh) | 2002-08-09 | 2009-10-28 | 詹森药业有限公司 | 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法 |
AU2003278766A1 (en) | 2002-09-04 | 2004-03-29 | Microchips, Inc. | Method and device for the controlled delivery of parathyroid hormone |
WO2004043433A2 (en) | 2002-11-08 | 2004-05-27 | Glaxo Group Limited | Pharmaceutical antiviral compositions |
MXPA05005146A (es) | 2002-11-15 | 2005-07-22 | Tibotec Pharm Ltd | Indolpiridinio sustituido como compuestos antiinfecciosos. |
AU2002350719A1 (en) | 2002-11-29 | 2004-06-23 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
CA2513527C (en) | 2003-02-07 | 2012-08-14 | Janssen Pharmaceutica N.V. | Pyrimidine derivatives for the prevention of hiv infection |
KR100629771B1 (ko) | 2004-01-27 | 2006-09-28 | 씨제이 주식회사 | 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법 |
BRPI0511900A (pt) | 2004-06-08 | 2008-01-22 | Vertex Pharma | composições farmacêuticas |
MY191349A (en) | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
EP1632232B3 (en) | 2004-09-02 | 2022-03-30 | Janssen Pharmaceutica NV | Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile |
AU2005279158C1 (en) | 2004-09-02 | 2010-12-16 | Janssen Pharmaceutica N.V. | Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile |
CA2587710C (en) | 2004-11-16 | 2014-10-21 | Elan Pharma International Ltd. | Injectable nanoparticulate olanzapine formulations |
TW201414495A (zh) | 2005-04-04 | 2014-04-16 | Tibotec Pharm Ltd | Hiv-感染之預防 |
TW200710091A (en) | 2005-04-11 | 2007-03-16 | Tibotec Pharm Ltd | (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors |
WO2006110889A2 (en) | 2005-04-11 | 2006-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Multi-layer structure having a predetermined layer pattern including an agent |
WO2006131806A2 (en) | 2005-06-07 | 2006-12-14 | Pfizer Products Inc. | Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release |
CN101272848B (zh) | 2005-07-28 | 2013-03-13 | Isp投资有限公司 | 改进喷雾干燥的粉末和颗粒材料性质的方法,以及由此生产的产品 |
RS52821B2 (sr) | 2006-01-20 | 2021-07-30 | Janssen Sciences Ireland Unlimited Co | Dugotrajno tretiranje hiv-infekcije sa tcm278 |
BR122020011487B1 (pt) | 2006-06-23 | 2024-02-20 | Janssen Sciences Ireland Uc | Composição farmacêutica compreendendo micro ou nanopartículas do composto tmc278 e seu processo de preparação |
US20080081064A1 (en) | 2006-09-28 | 2008-04-03 | Surmodics, Inc. | Implantable Medical Device with Apertures for Delivery of Bioactive Agents |
AR065720A1 (es) | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. |
US8426434B2 (en) | 2007-07-12 | 2013-04-23 | Tibotec Pharmaceuticals Ltd. | Crystalline form of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile |
US20090123508A1 (en) | 2007-10-04 | 2009-05-14 | Boston Scientific Scimed, Inc. | Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management |
WO2010047819A1 (en) | 2008-10-24 | 2010-04-29 | Concert Pharmaceuticals, Inc. | Hydroxyethylamino sulfonamide derivatives |
-
2004
- 2004-09-02 MY MYPI20043578A patent/MY169670A/en unknown
- 2004-09-03 KR KR1020067003074A patent/KR20060090658A/ko active Search and Examination
- 2004-09-03 NZ NZ545306A patent/NZ545306A/en unknown
- 2004-09-03 PL PL04787096.9T patent/PL1663240T5/pl unknown
- 2004-09-03 EP EP04787096.9A patent/EP1663240B2/en active Active
- 2004-09-03 AU AU2004268390A patent/AU2004268390B2/en active Active
- 2004-09-03 JP JP2006525150A patent/JP5507791B2/ja active Active
- 2004-09-03 US US10/570,228 patent/US20080200435A1/en not_active Abandoned
- 2004-09-03 CA CA2537095A patent/CA2537095C/en active Active
- 2004-09-03 WO PCT/EP2004/052028 patent/WO2005021001A1/en active Application Filing
- 2004-09-03 AP AP2006003551A patent/AP2109A/en active
- 2004-09-03 CN CN2004800254267A patent/CN101060844B/zh active Active
- 2004-09-03 MX MXPA06002437A patent/MXPA06002437A/es active IP Right Grant
-
2006
- 2006-01-30 IL IL173438A patent/IL173438A/en active Protection Beyond IP Right Term
- 2006-03-27 NO NO20061374A patent/NO334877B1/no active Protection Beyond IP Right Term
- 2006-12-05 HK HK06113340.4A patent/HK1092698A1/xx active IP Right Maintenance
-
2009
- 2009-10-07 US US12/574,881 patent/US8841310B2/en active Active
-
2011
- 2011-03-14 AU AU2011201123A patent/AU2011201123B2/en active Active
- 2011-05-24 IL IL213104A patent/IL213104A/en active IP Right Grant
- 2011-10-12 JP JP2011224982A patent/JP2012051915A/ja not_active Withdrawn
-
2014
- 2014-06-26 AU AU2014203484A patent/AU2014203484B2/en active Active
- 2014-08-07 US US14/454,045 patent/US20140349971A1/en not_active Abandoned
- 2014-10-31 JP JP2014222770A patent/JP5820045B2/ja active Active
- 2014-12-18 NO NO2014032C patent/NO2014032I1/no unknown
- 2014-12-18 NO NO2014030C patent/NO2014030I1/no unknown
- 2014-12-18 NO NO2014031C patent/NO2014031I1/no not_active IP Right Cessation
-
2015
- 2015-06-19 US US14/744,501 patent/US20150283135A1/en not_active Abandoned
- 2015-07-20 HR HRP20150798TT patent/HRP20150798T4/hr unknown
- 2015-10-20 NL NL300781C patent/NL300781I1/nl unknown
- 2015-10-20 LU LU92853C patent/LU92853I2/xx unknown
- 2015-10-21 CY CY2015039C patent/CY2015039I1/el unknown
- 2015-10-21 LU LU92855C patent/LU92855I2/xx unknown
- 2015-10-21 LU LU92854C patent/LU92854I2/xx unknown
- 2015-10-21 HU HUS1500054C patent/HUS1500054I1/hu unknown
- 2015-10-21 FR FR15C0073C patent/FR15C0073I2/fr active Active
- 2015-10-21 FR FR15C0072C patent/FR15C0072I2/fr active Active
- 2015-10-21 BE BE2015C053C patent/BE2015C053I2/fr unknown
- 2015-10-21 HU HUS1500052C patent/HUS1500052I1/hu unknown
- 2015-10-21 HU HUS1500053C patent/HUS1500053I1/hu unknown
- 2015-10-21 CY CY2015040C patent/CY2015040I1/el unknown
- 2015-10-21 CY CY2015038C patent/CY2015038I1/el unknown
- 2015-10-21 NL NL300768C patent/NL300768I2/nl unknown
- 2015-10-21 FR FR15C0071C patent/FR15C0071I2/fr active Active
-
2016
- 2016-08-05 AU AU2016210733A patent/AU2016210733B2/en active Active
- 2016-12-19 US US15/383,076 patent/US20170100398A1/en not_active Abandoned
- 2016-12-20 LT LTPA2016045C patent/LTPA2016045I1/lt unknown
- 2016-12-20 CY CY2016048C patent/CY2016048I1/el unknown
- 2016-12-20 NO NO2016025C patent/NO2016025I1/no unknown
- 2016-12-20 CY CY2016049C patent/CY2016049I2/el unknown
- 2016-12-20 FI FIEP04787096.9T patent/FI1663240T4/fi active
- 2016-12-20 HU HUS1600059C patent/HUS1600059I1/hu unknown
- 2016-12-20 LT LTPA2015035C patent/LTC1663240I2/lt unknown
- 2016-12-20 HU HUS1600058C patent/HUS1600058I1/hu unknown
-
2018
- 2018-04-11 US US15/950,548 patent/US20180228800A1/en not_active Abandoned
-
2019
- 2019-02-06 AU AU2019200813A patent/AU2019200813A1/en not_active Abandoned
- 2019-03-21 US US16/360,693 patent/US20190216807A1/en not_active Abandoned
-
2020
- 2020-02-07 US US16/784,404 patent/US20200171027A1/en not_active Abandoned
-
2021
- 2021-09-13 US US17/472,870 patent/US20220008417A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU92853I2 (fr) | Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine et l'emtricitabine | |
UA90518C2 (ru) | Фармацевтическая композиция в форме таблетки, которая имеет улучшеное всасывание при трансбукальном введение, которая содержит наркотический активный ингредиент и амин | |
BG108269A (en) | Pyrazolopyrimidines as therapeutic agents | |
BR0308452A (pt) | composições farmacêuticas e métodos de preparação de composição farmacêutica | |
ATE454138T1 (de) | Tablette mit modifizierter freisetzung von bupropion hydrochlorid | |
BR0308243A (pt) | Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero | |
BG108268A (en) | Pyrazolopyrimidines as therapeutic agents | |
EA200800880A1 (ru) | Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции | |
EE05107B1 (et) | Türosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning ühendi kasutamine | |
MA27372A1 (fr) | Forme posologique de pramipexole à administration une fois par jour | |
HRP20050253B1 (hr) | Diaril eteri kao opioid antagonisti opioidnih receptora | |
IS6886A (is) | Kínasólín sem MMP-13 hindrar | |
BR0209020A (pt) | Composição farmacêutica de polialilamina | |
PT1435915E (pt) | Formas de administração oral de propiverina ou de seus sais farmaceuticamente aceitáveis com libertação prolongada da substância activa | |
EP1450803A4 (en) | NEW USES FOR ANTIMALARIAL THERAPEUTIC AGENTS | |
MXPA05007609A (es) | Antagonista de un receptor sensible al calcio. | |
ATE308522T1 (de) | Opioidrezeptorantagonisten | |
SE0102440D0 (sv) | New compound | |
DK1267847T3 (da) | 5HT2-antagonist til regulering af IOP og behandling af glaucom | |
SG160197A1 (en) | Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist | |
ATE469642T1 (de) | Vorbeugungs- oder heilmittel gegen endometriose | |
DE602004016761D1 (de) | Tablettenformulierungen von venlafaxin mit verzögerter freisetzung | |
PL369736A1 (en) | New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors | |
DE60230785D1 (de) | Polymorphe marker die benutzt werden kann, um die wirksamkeit der interferon-therapie festzustellen | |
EE200300434A (et) | Farmatseutiliselt toimivate ühendite kasutamine |